Millie Nelson | BioProcess International

Millie Nelson

Editor, BioProcess Insider

Journalist covering global biopharmaceutical manufacturing and processing news and host of the Voices of Biotech podcast.

I am currently living and working in London but I grew up in Lincolnshire (UK) and studied in Newcastle (UK).

Got a story? Feel free to email me at [email protected]

Latest from Millie Nelson

Facilities & Capacity

Q&A: Vetter SVP says sustainability is essential for long-term success Q&A: Vetter SVP says sustainability is essential for long-term success

byMillie Nelson, Josh Abbott

Oct 29, 2024

6 Min Read

Upstream & Downstream Processing

Moving beyond protein translation with tRNA Moving beyond protein translation with tRNA

byJosh Abbott, Millie Nelson

Sep 13, 2024

6 Min Read

All from Millie Nelson

Podcast: Sustainability is about health equity, says ScaleReady and Germfree

Podcast: Sustainability is about health equity, says ScaleReady and Germfree

byMillie Nelson, Editor

Podcast: Sustainability at events is environmental and humanistic, says EBD

Podcast: Sustainability at events is environmental and humanistic, says EBD

byMillie Nelson, Editor

Pit or peak: Why your partnering strategy should not be market dependent

Pit or peak: Why your partnering strategy should not be market dependent

byMillie Nelson, Editor

Ipsen expands oncology partnership with Marengo

Ipsen expands oncology partnership with Marengo

byMillie Nelson, Editor

FDA advisors unanimously back Lilly’s Alzheimer's drug

FDA advisors unanimously back Lilly’s Alzheimer's drug

byMillie Nelson, Editor

US FDA grants GSK RSV vax label expansion

US FDA grants GSK RSV vax label expansion

byMillie Nelson, Editor

You cannot introduce more tech to a broken system, says GSK

You cannot introduce more tech to a broken system, says GSK

byMillie Nelson, Editor

Therapeutic Class

Adcendo to bolster ADC pipeline with $106m Series A funding

Adcendo to bolster ADC pipeline with $106m Series A funding

byMillie Nelson, Editor

BioNTech bags up to $145m from CEPI for African mRNA plants

BioNTech bags up to $145m from CEPI for African mRNA plants

byMillie Nelson, Editor

Merck adds ophthalmology assets with $1.3bn EyeBio buy

Merck adds ophthalmology assets with $1.3bn EyeBio buy

byMillie Nelson, Editor

Facilities & Capacity

NIBRT opens advanced therapies plant in Ireland

NIBRT opens advanced therapies plant in Ireland

byMillie Nelson, Editor

Facilities & Capacity

Lilly injects another $5.3bn in Indiana plant to up tirzepatide production

Lilly injects another $5.3bn in Indiana plant to up tirzepatide production

byMillie Nelson, Editor

MilliporeSigma to bolster viral vector capacity with $600m Mirus buy

MilliporeSigma to bolster viral vector capacity with $600m Mirus buy

byMillie Nelson, Editor

AstraZeneca weighs in again on obesity market with $80m funding for SixPeaks

AstraZeneca weighs in again on obesity market with $80m funding for SixPeaks

byMillie Nelson, Editor

Q1 2024: Merck KGaA cites volatile CDMO biz and destocking for declined sales

Q1 2024: Merck KGaA cites volatile CDMO biz and destocking for declined sales

byMillie Nelson, Editor

Facilities & Capacity

AstraZeneca to build $1.5bn ADC site in Singapore

AstraZeneca to build $1.5bn ADC site in Singapore

byMillie Nelson, Editor

Facilities & Capacity

Bolt Bio cuts workforce by 50% to refocus pipeline

Bolt Bio cuts workforce by 50% to refocus pipeline

byMillie Nelson, Editor

Podcast: Sustainability equals efficiency, says eXmoor

Podcast: Sustainability equals efficiency, says eXmoor

byMillie Nelson, Editor

From healthcare to health: 'No country can do this alone,' say experts in UAE

From healthcare to health: 'No country can do this alone,' say experts in UAE

byMillie Nelson, Editor

Sanofi inks $1.2bn Novavax deal to bolster post-pandemic vax sales

Sanofi inks $1.2bn Novavax deal to bolster post-pandemic vax sales

byMillie Nelson, Editor

Facilities & Capacity

Grand River expands capacity with Michigan fill/finish site

Grand River expands capacity with Michigan fill/finish site

byMillie Nelson, Editor

Facilities & Capacity

Wacker ups San Diego plant capacity

Wacker ups San Diego plant capacity

byMillie Nelson, Editor

Building successful teams in biotech: “The future is female and very colorful”

Building successful teams in biotech: “The future is female and very colorful”

byMillie Nelson, Editor

Upstream & Downstream Processing

Organizational flips help B-I deal with complexity challenges, says expert

Organizational flips help B-I deal with complexity challenges, says expert

byMillie Nelson, Editor

Alvotech to manufacture Humira biosimilar for Quallent

Alvotech to manufacture Humira biosimilar for Quallent

byMillie Nelson, Editor

Facilities & Capacity

Emergent cuts 300 jobs and shutters two facilities

Emergent cuts 300 jobs and shutters two facilities

byMillie Nelson, Editor

Ingersoll Rand to bolster life sci presence with $2.3bn ILC Dover buy

Ingersoll Rand to bolster life sci presence with $2.3bn ILC Dover buy

byMillie Nelson, Editor

BIOSECURE and Catalent deal could bag more biz for Thermo

BIOSECURE and Catalent deal could bag more biz for Thermo

byMillie Nelson, Editor

Panasonic and Shinobi team to develop cost-effective cell therapy tech

Panasonic and Shinobi team to develop cost-effective cell therapy tech

byMillie Nelson, Editor

Sartorius Q1: Sales down, orders up as recovery continues

Sartorius Q1: Sales down, orders up as recovery continues

byMillie Nelson, Editor

Bristol Myers Squibb inks $380m CAR-T capacity and supply deal with Cellares

Bristol Myers Squibb inks $380m CAR-T capacity and supply deal with Cellares

byMillie Nelson, Editor

Picking a CDMO? Gene therapy developers must demand a pilot study

Picking a CDMO? Gene therapy developers must demand a pilot study

byMillie Nelson, Editor

Corner Therapeutics bags $54m to create vaccines with ‘lifelong’ immunity

Corner Therapeutics bags $54m to create vaccines with ‘lifelong’ immunity

byMillie Nelson, Editor

Subscribe to receive our monthly print or digital publication

Join our 70,000+ readers. And yes, it's completely free.